Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
92.84 INR | -1.12% | +0.85% | +2.46% |
04-18 | Alembic Pharmaceuticals Board to Consider Dividend for Fiscal 2024; Shares Drop 3% | MT |
04-02 | Alembic Pharmaceuticals Gets US FDA Tentative Nod for Generic Breast Cancer Treatment | MT |
Sales 2022 | 782M 9.37M 12.9M | Sales 2023 | 1.27B 15.25M 20.99M | Capitalization | 15.22B 182M 251M |
---|---|---|---|---|---|
Net income 2022 | 2.22B 26.61M 36.64M | Net income 2023 | 1.91B 22.84M 31.44M | EV / Sales 2022 | 23.4 x |
Net cash position 2022 | 270M 3.24M 4.46M | Net cash position 2023 | 464M 5.55M 7.65M | EV / Sales 2023 | 11.6 x |
P/E ratio 2022 |
8.37
x | P/E ratio 2023 |
7.99
x | Employees | 271 |
Yield 2022 |
2.49% | Yield 2023 |
3.71% | Free-Float | 27.91% |
1 day | -1.12% | ||
1 week | +0.85% | ||
Current month | +10.97% | ||
1 month | +10.97% | ||
3 months | +0.53% | ||
6 months | +15.62% | ||
Current year | +2.46% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 69 | 88-07-01 | |
Rasesh J. Shah
DFI | Director of Finance/CFO | - | 14-08-12 |
Chairman | 76 | 67-08-19 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 76 | 67-08-19 | |
Chief Executive Officer | 69 | 88-07-01 | |
Director/Board Member | 44 | 13-04-23 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 92.84 | -1.12% | 23,142 |
24-04-29 | 93.89 | -0.33% | 19,395 |
24-04-26 | 94.2 | -0.65% | 150,736 |
24-04-25 | 94.82 | -0.87% | 25,415 |
24-04-24 | 95.65 | +2.08% | 34,995 |
Delayed Quote Bombay S.E., April 30, 2024 at 06:00 am
More quotes1st Jan change | Capi. | |
---|---|---|
+2.46% | 286M | |
+37.77% | 28.71B | |
-13.85% | 26.95B | |
+22.78% | 26.45B | |
+1.61% | 25.94B | |
+46.99% | 23.39B | |
+5.96% | 20.4B | |
-2.65% | 19.76B | |
+28.59% | 16.53B | |
-14.16% | 15.1B |
- Stock Market
- Equities
- ALEMBICLTD Stock